Bio-Techne (FRA:TE1) LT-Debt-to-Total-Asset : 0.14 (As of Dec. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Bio-Techne LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Bio-Techne's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.14.

Bio-Techne's long-term debt to total assets ratio declined from Dec. 2023 (0.20) to Dec. 2024 (0.14). It may suggest that Bio-Techne is progressively becoming less dependent on debt to grow their business.

Bio-Techne LT-Debt-to-Total-Asset Historical Data

The historical data trend for Bio-Techne's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Techne LT-Debt-to-Total-Asset Chart

Bio-Techne Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.20

0.18

0.13

0.17

0.15

Bio-Techne Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.20	0.18	0.15	0.14	0.14

Bio-Techne LT-Debt-to-Total-Asset Calculation

Bio-Techne's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (A: Jun. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Jun. 2024 )	/	Total Assets (A: Jun. 2024 )
	=	377.748	/	2511.892
	=	0.15

Bio-Techne's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	364.443	/	2550.255
	=	0.14

Bio-Techne (FRA:TE1) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Bio-Techne LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Bio-Techne's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Bio-Techne Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Techne Corp (FRA:TE1) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

TECH:USA

Address

614 McKinley Place N.E., Minneapolis, MN, USA, 55413

Website

https://www.bio-techne.com

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

Bio-Techne Headlines

No Headlines